FDA Grants Accelerated Approval for Anti-Amyloid Therapy, Lecanemab
On January 6, 2023, the FDA granted accelerated approval to Lecanemab (Leqembi). The drug shows a biological effect in removing a hallmark of Alzheimer’s disease pathology, beta-amyloid in individuals with[…]